Tag: LRRK2

A drug to lower activity of the protein LRRK2 — which is higher in some people with Parkinson’s — will move into a later-stage trial this year a...
The Michael J. Fox Foundation (MJFF) plays a critical role in convening partners and competitors to work together on new treatments and disease measur...
Increased caffeine intake is linked to a decreased risk of Parkinson’s disease (PD) in people who have a LRRK2 genetic mutation, which is associated...
Recent findings suggest LRRK2 kinase inhibitors—a type of Parkinson’s drug now being tested in clinical trials—may benefit a broad array of pati...
“Forbes” recently published a story detailing a “milestone moment” in the history of LRRK2 and the linchpin role of The Michae...
Denali Therapeutics has announced positive results from its first-in-human LRRK2 inhibitor clinical trial. The trial concluded that the experimental t...
Parkinson’s is a variable disease — different in age of onset, experience of symptoms and cause — but a new study points to a potential common l...
Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently an...
Today we share the research of Professor Glenda Halliday and Dr Nicholas Dzamko and the world leading LKK2 research they are conducting at The Univers...

SIGN UP FOR EMAIL UPDATES

GET PARKINSON'S RESEARCH NEWS, FOUNDATION UPDATES, INVITATIONS TO EVENTS AND MORE.